Logo
Homepage
Explore Our Models
My Cart
Contact
Subscribe
Models
Genetically Engineered Animals
Knockout Mice
Knockout Rats
Knockin Mice
Knockin Rats
Transgenic Mice
Transgenic Rats
Model Generation Techniques
Turboknockout<sup>®</sup> Gene Targeting
ES Cell Gene Targeting
Targeted Gene Editing
Regular Transgenic
PiggyBac Transgenesis
BAC Transgenic
Research Models
HUGO-GT™ Humanized Mice
Cre Mouse Lines
Humanized Target Gene Models
Metabolic Disease Models
Ophthalmic Disease Models
Neurological Disease Models
Autoimmune Disease Models
Immunodeficient Mouse Models
Humanized Immune System Mouse Models
Oncology & Immuno-oncology Models
Covid-19 Mouse Models
MouseAtlas Model Library
Knockout Cell Line Product Catalog
Tumor Cell Line Product Catalog
AAV Standard Product Catalog
Animal Supporting Services
Breeding Services
Cryopreservation & Recovery
Phenotyping Services
BAC Modification
Custom Cell Line Models
Induced Pluripotent Stem Cells (iPSCs)
Knockout Cell Lines
Knockin Cell Lines
Point Mutation Cell Lines
Overexpression Cell Lines
Virus Packaging
Adeno-associated Virus (AAV) Packaging
Lentivirus Packaging
Adenovirus Packaging
CRO Services
By Therapeutic Area
Oncology
Ophthalmology
Neuroscience
Metabolic & Cardiovascular Diseases
Autoimmune & Inflammatory
By Drug Type
AI-Powered AAV Discovery
Gene Therapy
Oligonucleotide Therapy
Antibody Therapy
Cell Immunotherapy
Resources
Promotion
Events & Webinars
Newsroom
Blogs & Insights
Resource Vault
Reference Databases
Peer-Reviewed Citations
Rare Disease Data Center
AbSeek
Cell iGeneEditor™ System
OriCell
Quality
Facility Overview
Animal Health & Welfare
Health Reports
About Us
Corporate Overview
Our Partners
Careers
Contact Us
Login
Request a Product Quote
Select products from our catalogs and submit your request. Our team will get back to you with detailed information.
Full Name
Email
Phone Number
Organization
Job Role
Country
Catalog Type
Product Name
Additional Comments
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
C57BL/6NCya-Tm6sf2em1/Cya
Common Name:
Tm6sf2-KO
Product ID:
S-KO-00541
Background:
C57BL/6NCya
Product Type
Age
Genotype
Sex
Quantity
Price:
Contact for Pricing
Basic Information
Strain Name
Tm6sf2-KO
Strain ID
KOCMP-107770-Tm6sf2-B6N-VA
Gene Name
Tm6sf2
Product ID
S-KO-00541
Gene Alias
--
Background
C57BL/6NCya
NCBI ID
107770
Modification
Conventional knockout
Chromosome
8
Phenotype
MGI:1933210
Document
Click here to download >>
Application
--
More
Rare Disease Data Center >>
Note
Note: When using this mouse strain in a publication, please cite “C57BL/6NCya-Tm6sf2em1/Cya mice (Catalog S-KO-00541) were purchased from Cyagen.”
Strain Description
Ensembl Number
ENSMUST00000110160
NCBI RefSeq
NM_001293795
Target Region
Exon 2~9
Size of Effective Region
~4.6 kb
Detailed Document
Click here to download >>
Overview of Gene Research
Tm6sf2, or Transmembrane 6 superfamily member 2, is located on chromosome 19 (19p12) and has emerged as a key regulator in lipid metabolism [1,2]. It is involved in pathways such as intestinal cholesterol absorption, hepatic cholesterol biosynthesis and transport, and very-low-density lipoprotein (VLDL) lipidation [1,5,7]. Genetic studies have associated Tm6sf2 variants with plasma lipid traits, cardiovascular disease (CVD), and non-alcoholic fatty liver disease (NAFLD), highlighting its biological importance [1,2,8]. Mouse models with overexpression or knockdown/knockout of Tm6sf2 have been crucial for in vivo validation of its role in regulating plasma lipid levels [1].

In mouse models, hepatocyte-specific Tm6sf2 knockout (Tm6sf2 ∆hep) exacerbated tumour formation in metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma (MASLD-HCC), while overexpression had opposite effects, suggesting Tm6sf2 can promote antitumour immunity via inhibiting the NF-κB signalling pathway to activate cytotoxic CD8+ T cells [3]. Myeloid cell-specific Tm6sf2 knockout (LysM Cre+/Tm6sf2fl/fl/ApoE-/-, TM6 mKO) inhibited atherosclerosis and decreased foam cells in plaques without changing plasma lipid profiles, as RNA sequencing showed downregulation of genes related to inflammation, cholesterol uptake, and endoplasmic reticulum stress in bone marrow-derived macrophages [4]. Tm6sf2 -/- rats had higher hepatic triglyceride content and lower plasma cholesterol levels, with reduced rates of dietary and hepatic triglyceride appearance in blood, and decreased lipid content in newly secreted VLDLs, indicating Tm6sf2 acts in the smooth endoplasmic reticulum to promote VLDL lipidation [5]. Tm6sf2 intestinal epithelial cell-specific knockout (Tm6sf2ΔIEC) in mice led to MASH, accompanied by intestinal barrier impairment and microbial dysbiosis [6].

In conclusion, Tm6sf2 is a significant regulator in lipid metabolism, playing key roles in various disease-related processes. Gene knockout mouse models have been instrumental in revealing its functions in diseases like MASLD-HCC, atherosclerosis, and MASH, providing valuable insights into the underlying mechanisms and potential therapeutic targets [3,4,6].

References:

1. Li, Ting-Ting, Li, Tao-Hua, Peng, Juan, Zheng, Xi-Long, Tang, Zhi-Han. 2017. TM6SF2: A novel target for plasma lipid regulation. In Atherosclerosis, 268, 170-176. doi:10.1016/j.atherosclerosis.2017.11.033. https://pubmed.ncbi.nlm.nih.gov/29232562/

2. Luo, Fei, Oldoni, Federico, Das, Avash. 2021. TM6SF2: A Novel Genetic Player in Nonalcoholic Fatty Liver and Cardiovascular Disease. In Hepatology communications, 6, 448-460. doi:10.1002/hep4.1822. https://pubmed.ncbi.nlm.nih.gov/34532996/

3. Zhang, Yating, Xie, Mingxu, Wen, Jun, Yu, Jun, Zhang, Xiang. 2025. Hepatic TM6SF2 activates antitumour immunity to suppress metabolic dysfunction-associated steatotic liver disease-related hepatocellular carcinoma and boosts immunotherapy. In Gut, 74, 639-651. doi:10.1136/gutjnl-2024-333154. https://pubmed.ncbi.nlm.nih.gov/39667906/

4. Zhu, Wenzhen, Liang, Wenying, Lu, Haocheng, Chen, Y Eugene, Guo, Yanhong. 2022. Myeloid TM6SF2 Deficiency Inhibits Atherosclerosis. In Cells, 11, . doi:10.3390/cells11182877. https://pubmed.ncbi.nlm.nih.gov/36139452/

5. Luo, Fei, Smagris, Eriks, Martin, Sarah A, Hobbs, Helen H, Cohen, Jonathan C. 2021. Hepatic TM6SF2 Is Required for Lipidation of VLDL in a Pre-Golgi Compartment in Mice and Rats. In Cellular and molecular gastroenterology and hepatology, 13, 879-899. doi:10.1016/j.jcmgh.2021.12.008. https://pubmed.ncbi.nlm.nih.gov/34923175/

6. Zhang, Xiang, Lau, Harry Cheuk-Hay, Ha, Suki, Wong, Vincent Wai-Sun, Yu, Jun. 2025. Intestinal TM6SF2 protects against metabolic dysfunction-associated steatohepatitis through the gut-liver axis. In Nature metabolism, 7, 102-119. doi:10.1038/s42255-024-01177-7. https://pubmed.ncbi.nlm.nih.gov/39779889/

7. Liu, Jing, Ginsberg, Henry N, Reyes-Soffer, Gissette. 2024. Basic and translational evidence supporting the role of TM6SF2 in VLDL metabolism. In Current opinion in lipidology, 35, 157-161. doi:10.1097/MOL.0000000000000930. https://pubmed.ncbi.nlm.nih.gov/38465912/

8. Chen, Li-Zhen, Xia, Harry Hua-Xiang, Xin, Yong-Ning, Lin, Zhong-Hua, Xuan, Shi-Ying. 2015. TM6SF2 E167K Variant, a Novel Genetic Susceptibility Variant, Contributing to Nonalcoholic Fatty Liver Disease. In Journal of clinical and translational hepatology, 3, 265-70. doi:10.14218/JCTH.2015.00023. https://pubmed.ncbi.nlm.nih.gov/26807382/

Quality Control Standard
Sperm Test

Pre-cryopreservation: Measurement of sperm concentration, determination of sperm viability.

Post-cryopreservation: A vial of cryopreserved sperms is selected for in-vitro fertilization from each batch.

Environmental Standards:SPF
Available Region:Global
Source:Cyagen
Model Library
Model Library
Resources
Resources
Animal Quality
Animal Quality
Get Support
Get Support
Address:
2255 Martin Avenue, Suite E Santa Clara, CA 95050-2709, US
Tel:
800-921-8930 (8-6pm PST)
+1408-963-0306 (lnt’l)
Fax:
408-969-0338
Email:
animal-service@cyagen.com
service@cyagen.us
CRO Services
OncologyOphthalmologyNeuroscienceMetabolic & CardiovascularAutoimmune & InflammatoryGene TherapyAntibody Therapy
About Us
Corporate OverviewOur PartnersCareersContact Us
Social Media
Disclaimer: Pricing and availability of our products and services vary by region. Listed prices are applicable to the specific countries. Please contact us for more information.
Copyright © 2025 Cyagen. All rights reserved.
Privacy Policy
Site Map
Stay Updated with the Latest from Cyagen
Get the latest news on our research models, CRO services, scientific resources, and special offers—tailored to your research needs and delivered straight to your inbox.
Full Name
Email
Organization
Country
Areas of Interest